766 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
ABBV AbbVie Inc. $95.37 $144.42B N/A
Article Searches
Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales https://www.fool.com/investing/2017/05/02/gilead-sciences-incs-revenue-and-earnings-continue.aspx?source=iedfolrf0000001 May 02, 2017 - The big biotech's revenue and earnings fell yet again in Q1. But there were a few bright spots.
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/258295/abbvie-abbv-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-258295 Apr 27, 2017 - AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
AbbVie (ABBV) Q1 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4066300-abbvie-abbv-q1-2017-results-earnings-call-transcript?source=feed_sector_healthcare Apr 27, 2017 - AbbVie, Inc. (NYSE:ABBV)Q1 2017 Earnings CallApril 27, 2017 9:00 am ETExecutivesElizabeth Shea - AbbVie, Inc.Richard A. Gonzalez - AbbVie, Inc.Michael E. Severino - AbbVie, Inc.William J. Chase - AbbV
What Can Stop the World's Best Selling Drug? https://www.wsj.com/articles/what-can-stop-the-worlds-best-selling-drug-1493312098?mod=rss_markets_main Apr 27, 2017 - AbbVie rides its blockbuster anti-inflammatory drug, Humira, to another strong quarter, but the question remains: How long can this juggernaut can last?
AbbVie (ABBV) Beats Earnings and Revenue in Q1 http://www.zacks.com/stock/news/258165/abbvie-abbv-beats-earnings-and-revenue-in-q1?cid=CS-ZC-FT-258165 Apr 27, 2017 - AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26.
5 Fantastic Earnings Charts http://www.zacks.com/stock/news/258032/5-fantastic-earnings-charts?cid=CS-ZC-FT-258032 Apr 26, 2017 - Tracey brings you the companies with the best earnings charts each week.
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY http://www.zacks.com/stock/news/257833/pharma-stocks-q1-earnings-roster-for-apr-27-celg-abbv-bmy?cid=CS-ZC-FT-257833 Apr 26, 2017 - Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates? http://www.zacks.com/stock/news/257795/gilead-gild-q1-earnings-stock-likely-to-beat-estimates?cid=CS-ZC-FT-257795 Apr 25, 2017 - Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong http://www.zacks.com/stock/news/257731/biogen-biib-q1-earnings-sales-top-spinraza-sales-strong?cid=CS-ZC-FT-257731 Apr 25, 2017 - Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
Bleak Outlook for Big Drug Makers https://www.wsj.com/articles/bleak-outlook-for-big-drug-makers-1493051153?mod=rss_markets_main Apr 25, 2017 - Without price increases or deals to boost earnings, the pharmaceuticals sector faces a weak earnings season.
<<<Page 71>